Lutemax 2020
Natural health product licensed in Canada
- Other names
- 2020-OS-20
- Licence holder
- OmniActive Health Technologies, Inc.
- NPN or DIN-HM
- 80081863
- Status
- Active licence
- Licence date
- 14 December 2017
- Revision date
- 13 March 2023
- Form
- Capsule, remplie de liquide
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| (3R,3'S)-b,b-carotène-3,3'-diol Source : Zeaxanthin | 1 mg | Not calculated |
| (3R,3'R)-bêta,bêta-Carotène-3,3'-diol Source : Tagetes erecta - Oléorésine (herbe en fleurs) | 1 mg | Not calculated |
| (3R,3'R)-bêta,bêta-Carotène-3,3'-diol Source : Zeaxanthin | 1 mg | Not calculated |
| (3R,3'R,6'R)-bêta,epsilon-carotène-3,3'-diol Source : Lutéine(USP) | 10 mg | Not calculated |
| (3R,3'R,6'R)-bêta,epsilon-carotène-3,3'-diol Source : Tagetes erecta - Oléorésine (herbe en fleurs) | 10 mg | Not calculated |
Non-medicinal ingredients
NA, Huile de soja, Tocophérols, Huile de tournesol, Hypromellose, Huile de carthame
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 2 days |
Uses authorised in Canada
Text supplied in English because no French text is available.
Antioxidant for the maintenance of good health. Antioxidant for the maintenance of eye health. Helps to support eye health in conditions (associated with sunlight damage), such as cataracts and age-related macular degeneration. Helps to maintain eye health in conditions (associated with sunlight damage), such as cataracts and age-related macular degeneration. Helps to reduce the risk of developing cataracts. Clinically proven to help improve macular pigment optical density. Helps improve macular pigment optical density, which helps protect the eyes (retina) by filtering out the damaging blue light. Helps to protect the eyes against both blue light and oxidative damage. Helps improve contrast sensitivity. Helps improve visual acuity in persons with age-related macular degeneration. Helps to improve glare recovery.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80081863
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2023. Photograph the packaging to check whether it has changed. Photograph the packaging